Date — Jan 1 - Dec 31
Speaker: BT Slingsby, M.D., Ph.D., M.P.H.Chief Executive Officer, The Global Health Innovative Technology Fund
Duration: Approx. 1 hour *Please note that due to technical issues at the time of this recording, there are two periods of interruption in the webinar. The first interruption occurs between 29:30-34:00 and the second interruption occurs between 35:30-40:00
This webinar is available on demand. After you pay for it, you’ll receive a link that you can use to access it at your own convenience.
The Global Health Innovative Technology Fund (GHIT Fund) is Japan’s first public-private partnership to advance the development of new health technologies for the developing world. The Fund is supported by the Japanese Government, United Nations Development Programme (UNDP), Japan’s leading pharmaceutical companies, and the Bill & Melinda Gates Foundation. The GHIT Fund supports partnerships between Japanese and non-Japanese organizations to develop new medicines, vaccines and diagnostics targeting neglected diseases. Organizations eligible to participate in grant-funded research include pharma companies with R&D facilities in Japan, product development partnerships, biotechnology companies, not-for-profit research organizations, government research institutions and academic institutions. Five Japanese pharma companies are supporting the Fund: Astellas, Eisai, Daiichi Sankyo, Shionogi and Takeda.
In this webinar, Dr. BT Slingsby, CEO of the GHIT Fund, will examine a wide range of topics related to the Fund, including:
- Current challenges in global health R&D
- The Collaborative R&D approach of Product Development Partnerships
- Overview of the operational framework of the GHIT Fund
- Description of current projects supported by the Fund and update on new grant opportunities
- Important considerations for organizations seeking grant support from the GHIT Fund, including the Fund’s current research priorities and grant eligibility requirements
Before joining the GHIT Fund, Dr. Slingsby was involved in the founding of for-profit and non-profit entities in the U.S. and Japan, and from 2010 to 2013, he was responsible for global access strategies for Eisai Co., Ltd. Dr. Slingsby graduated from Brown University, earned his Masters and Doctorate from Kyoto University and The University of Tokyo, and received his Medical Doctorate from The George Washington University.